Breaking News, Collaborations & Alliances

Janssen, Halozyme in Global Drug Development Pact

To develop and commercialize Janssen products with ENHANZE technology

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Halozyme Therapeutics, Inc. has entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize products combining Janssen compounds with Halozyme’s ENHANZE technology. ENHANZE is based on a recombinant human hyaluronidase enzyme (rHuPH20) that temporarily modifies hyaluronan to aid in the dispersion and absorption of other injected drugs.   Halozyme has granted Janssen a worldwide license to develop and commercialize products for as man...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters